Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=11
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=11
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=11
PubPharm (7.806)
101
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation : A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
102
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients : Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
103
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) : A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
104
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma : Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
105
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma : A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
106
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma : Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
107
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) : MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
108
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) : MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Except Basal Cell Skin Carcinoma) With Smoothened (SMO) or Patched 1 (PTCH1) Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
109
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) : MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
110
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma : Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
6
7
8
9
10
11
12
13
14
15
16
Nächster »
[781]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
7.806
Aufsätze
7.806
E-Artikel
7.806
E-Ressourcen
Zeitschriftentitel
4.588
WHO International Clinical Trials Registry Plat...
3.218
ClinicalTrials.gov
Thema
7.806
610
6.935
Study Type: Interventional
3.170
Multiple Myeloma
2.647
Neoplasms, Plasma Cell
2.056
Recruitment Status: Not yet recruiting
1.944
Phase: Phase 2
1.671
Phase: Phase 3
1.520
Recruitment Status: Completed
1.376
Recruitment Status: Authorised-recruitment may ...
1.327
Recruitment Status: Recruiting
1.007
Medical Condition: Multiple Myeloma
985
Phase: Phase 1
775
Study Type: Observational
471
Recruitment Status: Active, not recruiting
397
Lymphoma
380
Recruitment Status: Terminated
316
Leukemia
258
Phase: Phase 1/Phase 2
250
Myelodysplastic Syndromes
234
Phase: Phase 1, Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.854
2020-
2.898
2010-2019
54
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.676
Englisch
88
Unbestimmt
14
Spanisch
8
Dänisch
8
Französisch
6
Deutsch
2
Tschechisch
2
Galizisch
2
Kinyarwanda
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...